Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
2 hedge funds and large institutions have $4K invested in Allena Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 23 closing their positions.
92% less funds holding
Funds holding: 25 → 2 (-23)
100% less capital invested
Capital invested by funds: $1.71M → $4K (-$1.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 23
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$533K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$512K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$135K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$73K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$68K |
ALNA Hedge Fund Activity: Q3 2022 in Review
2 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q3 2022, worth a combined $4K — down 100% from $1.71M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ALNA and 0 opened new positions — a net loss of 23 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was TRV GP II, exiting entirely with an estimated $533K sold.
- 2 institutional investors held Allena Pharmaceuticals (ALNA) as of Q3 2022, down from 25 in Q2 2022.
- Funds reported $4K of Allena Pharmaceuticals stock for Q3 2022, down 100% quarter-over-quarter.
- 0 funds opened new Allena Pharmaceuticals positions in Q3 2022 and 23 closed out, a net change of -23 holders.
- The largest Allena Pharmaceuticals seller in Q3 2022 was TRV GP II, an estimated $533K sold.
Based on aggregated 13F filings for Q3 2022.